Comparing two treatments for recurrent Clostridioides difficile infection
Comparison of defined live biotherapeutic product and fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection
This study is looking at how well a special live treatment works compared to a stool transplant for people who keep getting C. difficile infections, to see if it can help them feel better and improve their gut health in a safer way.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10845658 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of a defined live biotherapeutic product (LBP) compared to fecal microbiota transplantation (FMT) for treating recurrent Clostridioides difficile infection (rCDI). The study aims to assess how well these treatments work and how they affect the gut microbiome. Patients will receive either the LBP or FMT, and their clinical responses and microbial changes will be closely monitored. This approach seeks to provide a safer and more standardized treatment option for rCDI.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing recurrent Clostridioides difficile infections who have not responded to standard antibiotic treatments.
Not a fit: Patients with a single episode of Clostridioides difficile infection or those who have contraindications for either treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for patients suffering from recurrent Clostridioides difficile infections.
How similar studies have performed: Previous research has shown that fecal microbiota transplantation is effective for treating rCDI, but this approach using defined live biotherapeutic products is relatively novel.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Faith, Jeremiah James — Icahn School of Medicine at Mount Sinai
- Study coordinator: Faith, Jeremiah James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.